U.S.-China trade agreement; CPI ahead this week - what’s moving markets By Investing.com
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 12 2025
0mins
Source: Investing.com
U.S.-China Trade Agreement: U.S. stock futures surged after the announcement of a significant reduction in tariffs between the U.S. and China, with both countries agreeing to a 90-day pause on escalating tariffs, which has alleviated investor concerns about a potential global economic crisis.
Impact on Pharmaceutical Stocks: Pharmaceutical stocks declined following President Trump's plan to sign an executive order aimed at reducing drug prices by aligning U.S. costs with those in other high-income countries, potentially affecting the profitability of international drugmakers reliant on the U.S. market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVO
Wall Street analysts forecast NVO stock price to rise
8 Analyst Rating
4 Buy
3 Hold
1 Sell
Moderate Buy
Current: 38.520
Low
42.00
Averages
54.67
High
70.00
Current: 38.520
Low
42.00
Averages
54.67
High
70.00
About NVO
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Amazon Launches GLP-1 Weight Management Program
- Service Launch: Amazon One Medical has announced a weight management program centered around GLP-1 treatments, aiming to address obesity as a chronic condition by integrating medical services to provide personalized solutions, thereby enhancing the overall healthcare experience for patients.
- Drug Accessibility: The program allows patients to order popular GLP-1 medications, including Foundayo and oral Wegovy, online at prices comparable to the market, while also offering 24/7 prescription renewals, significantly simplifying the weight loss journey for patients.
- Market Potential: With the surging demand for GLP-1 drugs, Amazon's weight management program is poised to attract a large number of patients, potentially driving revenue growth for Amazon One Medical through membership fees and medical services, thereby enhancing its competitiveness in the healthcare sector.
- Strategic Implications: Although Amazon's cloud computing business remains its primary profit driver, the weight management program could emerge as a significant growth engine for its healthcare services, further solidifying Amazon's position in the rapidly expanding GLP-1 market.
See More
Amazon Launches GLP-1 Weight Management Program
- Market Potential: The GLP-1 drug market is projected to approach $100 billion by 2030, with Eli Lilly and Novo Nordisk dominating the space and recently launching oral medications Foundayo and Wegovy, indicating strong market demand and competitive pressure.
- Amazon's Healthcare Strategy: Amazon is leveraging its One Medical platform to launch a GLP-1 weight management program that integrates virtual and in-person medical services, aiming to provide personalized weight loss solutions that cater to patients' needs for convenient healthcare, thereby enhancing its competitiveness in the healthcare sector.
- Convenient Access to Medications: Patients can easily order GLP-1 medications through Amazon One Medical, benefiting from fast delivery services, while existing patients enjoy 24/7 prescription renewals, which may attract more patients to choose Amazon as their preferred weight loss platform.
- Growth Drivers: Amazon's weight management program is expected to drive growth for One Medical through membership fees and medical service revenues; although GLP-1 drugs may not become a major growth engine for Amazon's overall business, they could represent a significant revenue source within its healthcare services ecosystem.
See More
Lilly and Novo Nordisk Compete in Oral Obesity Drug Market
- Market Performance Comparison: Lilly's oral obesity drug Foundayo garnered 3,707 prescriptions in its second week, significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in the same period, indicating a weaker market acceptance for Lilly that could impact future sales performance.
- Prescription Growth Discrepancy: Foundayo only received 1,390 prescriptions in its debut week, while Wegovy reached 3,071 prescriptions in its first four days, highlighting Novo's clear advantage in market promotion and consumer acceptance, potentially leading to a loss of market share for Lilly.
- FDA Approval and Market Outlook: Foundayo was approved by the FDA earlier this month for use alongside a reduced-calorie diet and increased physical activity; however, despite showing significant weight loss in clinical trials, the market response has not met expectations, which may affect the company's long-term strategy.
- Investor Sentiment Shift: Although Lilly's stock fell 4% on Friday, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating market expectations for future potential, which may provide support for the company's subsequent performance.
See More
Eli Lilly's Foundayo Faces Sales Challenges Post FDA Approval
- Initial Prescription Struggles: Eli Lilly's Foundayo received only 1,390 prescriptions in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to Novo Nordisk's Wegovy, which garnered 18,410 prescriptions, indicating a concerning market reception that could impact future sales expectations.
- Stock Price Decline Reflects Concerns: The disappointing initial sales performance led to a nearly 4% drop in Eli Lilly's stock price on Friday, reflecting investor skepticism about the new product's viability, which may result in short-term capital outflows and affect the company's market capitalization.
- Intensifying Market Competition: As Eli Lilly's first FDA-approved weight-loss pill, Foundayo faces formidable competition from Wegovy, which has already established a strong reputation and sales record, complicating Foundayo's market outlook and necessitating close monitoring of its subsequent performance.
- Long-Term Potential Remains: Despite Foundayo's poor initial sales data, Eli Lilly, as a major pharmaceutical company with a diverse product portfolio, has demonstrated potential in the weight-loss category with Zepbound's success, suggesting that investors should focus on long-term growth rather than short-term fluctuations.
See More
Eli Lilly's New Drug Sales Underwhelm Investors
- New Drug Sales Performance: Eli Lilly's weight loss pill Foundayo was prescribed only 1,390 times in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to rival Novo Nordisk's Wegovy, which saw 18,410 prescriptions in its second week, indicating a significant market acceptance gap.
- Stock Price Fluctuation: Concerns over Foundayo's sales outlook led to a nearly 4% drop in Eli Lilly's stock price during the trading session, reflecting investor skepticism about the new product's potential, which could impact the company's future financing and investment strategies.
- Competitive Market Pressure: While Eli Lilly has seen success with Zepbound, the disappointing initial performance of Foundayo raises concerns about its competitive position in the rapidly growing weight loss market, necessitating close monitoring of its subsequent sales data.
- Long-Term Outlook: Eli Lilly noted that the sales data for Foundayo may require time for a comprehensive assessment; despite the initial underperformance, the company's diversified strategy in drug development and market positioning still provides a stable growth foundation.
See More
Midday Market Moves: Notable Stock Fluctuations
- Comcast Downgrade: Comcast's stock fell nearly 8% after Deutsche Bank downgraded its rating from Buy to Hold, with analysts indicating that while there is visibility into sustainable revenue and EBITDA growth, they do not expect multiple expansion, highlighting challenges in a stable but non-growing business environment.
- HCA Healthcare Decline: HCA Healthcare's stock dropped over 7% due to a milder flu season resulting in fewer patient admissions, and although the company narrowly beat analyst profit estimates, investors are concerned about declining patient demand as Affordable Care Act subsidies phase out.
- Organon Surge: Organon's stock spiked 22% following a report from The Economic Times that Sun Pharma plans to submit a $13 billion offer for the U.S.-based company, which could significantly enhance Organon's market value and investor confidence.
- Intel Earnings Beat: Intel reported first-quarter earnings of 29 cents per share on revenue of $13.58 billion, both exceeding Wall Street expectations, leading to a stock rally of over 23%, indicating a strong recovery momentum in the semiconductor market that may boost overall industry investment enthusiasm.
See More
Amazon Launches GLP-1 Weight Management Program
- Service Launch: Amazon One Medical has announced a weight management program centered around GLP-1 treatments, aiming to address obesity as a chronic condition by integrating medical services to provide personalized solutions, thereby enhancing the overall healthcare experience for patients.
- Drug Accessibility: The program allows patients to order popular GLP-1 medications, including Foundayo and oral Wegovy, online at prices comparable to the market, while also offering 24/7 prescription renewals, significantly simplifying the weight loss journey for patients.
- Market Potential: With the surging demand for GLP-1 drugs, Amazon's weight management program is poised to attract a large number of patients, potentially driving revenue growth for Amazon One Medical through membership fees and medical services, thereby enhancing its competitiveness in the healthcare sector.
- Strategic Implications: Although Amazon's cloud computing business remains its primary profit driver, the weight management program could emerge as a significant growth engine for its healthcare services, further solidifying Amazon's position in the rapidly expanding GLP-1 market.
See More
Amazon Launches GLP-1 Weight Management Program
- Market Potential: The GLP-1 drug market is projected to approach $100 billion by 2030, with Eli Lilly and Novo Nordisk dominating the space and recently launching oral medications Foundayo and Wegovy, indicating strong market demand and competitive pressure.
- Amazon's Healthcare Strategy: Amazon is leveraging its One Medical platform to launch a GLP-1 weight management program that integrates virtual and in-person medical services, aiming to provide personalized weight loss solutions that cater to patients' needs for convenient healthcare, thereby enhancing its competitiveness in the healthcare sector.
- Convenient Access to Medications: Patients can easily order GLP-1 medications through Amazon One Medical, benefiting from fast delivery services, while existing patients enjoy 24/7 prescription renewals, which may attract more patients to choose Amazon as their preferred weight loss platform.
- Growth Drivers: Amazon's weight management program is expected to drive growth for One Medical through membership fees and medical service revenues; although GLP-1 drugs may not become a major growth engine for Amazon's overall business, they could represent a significant revenue source within its healthcare services ecosystem.
See More
Lilly and Novo Nordisk Compete in Oral Obesity Drug Market
- Market Performance Comparison: Lilly's oral obesity drug Foundayo garnered 3,707 prescriptions in its second week, significantly lower than Novo Nordisk's Wegovy, which achieved 18,410 prescriptions in the same period, indicating a weaker market acceptance for Lilly that could impact future sales performance.
- Prescription Growth Discrepancy: Foundayo only received 1,390 prescriptions in its debut week, while Wegovy reached 3,071 prescriptions in its first four days, highlighting Novo's clear advantage in market promotion and consumer acceptance, potentially leading to a loss of market share for Lilly.
- FDA Approval and Market Outlook: Foundayo was approved by the FDA earlier this month for use alongside a reduced-calorie diet and increased physical activity; however, despite showing significant weight loss in clinical trials, the market response has not met expectations, which may affect the company's long-term strategy.
- Investor Sentiment Shift: Although Lilly's stock fell 4% on Friday, retail sentiment on Stocktwits shifted from 'neutral' to 'bullish', indicating market expectations for future potential, which may provide support for the company's subsequent performance.
See More
Eli Lilly's Foundayo Faces Sales Challenges Post FDA Approval
- Initial Prescription Struggles: Eli Lilly's Foundayo received only 1,390 prescriptions in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to Novo Nordisk's Wegovy, which garnered 18,410 prescriptions, indicating a concerning market reception that could impact future sales expectations.
- Stock Price Decline Reflects Concerns: The disappointing initial sales performance led to a nearly 4% drop in Eli Lilly's stock price on Friday, reflecting investor skepticism about the new product's viability, which may result in short-term capital outflows and affect the company's market capitalization.
- Intensifying Market Competition: As Eli Lilly's first FDA-approved weight-loss pill, Foundayo faces formidable competition from Wegovy, which has already established a strong reputation and sales record, complicating Foundayo's market outlook and necessitating close monitoring of its subsequent performance.
- Long-Term Potential Remains: Despite Foundayo's poor initial sales data, Eli Lilly, as a major pharmaceutical company with a diverse product portfolio, has demonstrated potential in the weight-loss category with Zepbound's success, suggesting that investors should focus on long-term growth rather than short-term fluctuations.
See More
Eli Lilly's New Drug Sales Underwhelm Investors
- New Drug Sales Performance: Eli Lilly's weight loss pill Foundayo was prescribed only 1,390 times in its first week post-FDA approval, increasing to 3,707 in the second week, yet this pales in comparison to rival Novo Nordisk's Wegovy, which saw 18,410 prescriptions in its second week, indicating a significant market acceptance gap.
- Stock Price Fluctuation: Concerns over Foundayo's sales outlook led to a nearly 4% drop in Eli Lilly's stock price during the trading session, reflecting investor skepticism about the new product's potential, which could impact the company's future financing and investment strategies.
- Competitive Market Pressure: While Eli Lilly has seen success with Zepbound, the disappointing initial performance of Foundayo raises concerns about its competitive position in the rapidly growing weight loss market, necessitating close monitoring of its subsequent sales data.
- Long-Term Outlook: Eli Lilly noted that the sales data for Foundayo may require time for a comprehensive assessment; despite the initial underperformance, the company's diversified strategy in drug development and market positioning still provides a stable growth foundation.
See More
Midday Market Moves: Notable Stock Fluctuations
- Comcast Downgrade: Comcast's stock fell nearly 8% after Deutsche Bank downgraded its rating from Buy to Hold, with analysts indicating that while there is visibility into sustainable revenue and EBITDA growth, they do not expect multiple expansion, highlighting challenges in a stable but non-growing business environment.
- HCA Healthcare Decline: HCA Healthcare's stock dropped over 7% due to a milder flu season resulting in fewer patient admissions, and although the company narrowly beat analyst profit estimates, investors are concerned about declining patient demand as Affordable Care Act subsidies phase out.
- Organon Surge: Organon's stock spiked 22% following a report from The Economic Times that Sun Pharma plans to submit a $13 billion offer for the U.S.-based company, which could significantly enhance Organon's market value and investor confidence.
- Intel Earnings Beat: Intel reported first-quarter earnings of 29 cents per share on revenue of $13.58 billion, both exceeding Wall Street expectations, leading to a stock rally of over 23%, indicating a strong recovery momentum in the semiconductor market that may boost overall industry investment enthusiasm.
See More
